ALK-Abello A/S
CSE:ALK B
Operating Margin
ALK-Abello A/S
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| DK |
|
ALK-Abello A/S
CSE:ALK B
|
40.2B DKK |
22%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
744B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
362.6B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.8B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
186.5B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
163.6B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
199.5B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
135.8B USD |
27%
|
ALK-Abello A/S
Glance View
ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on ALK-Abello A/S's most recent financial statements, the company has Operating Margin of 21.8%.
You don't have any saved screeners yet